Brief: HBM's Unit Enters Into License Agreement With Visterra
12/06/2025 16:00
June 12 (Reuters) - Hbm Holdings Ltd 2142.HK: UNIT ENTERED INTO A LICENSE AGREEMENT WITH VISTERRA, INC AGREEMENT TO ADVANCE VISTERRA'S NEXT-GENERATION BIOTHERAPEUTIC PIPELINE FOR IMMUNE-MEDIATED AND AUTOIMMUNE DISEASES Further company coverage: 2142.HK ((Reuters.Briefs@thomsonreuters.com))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study